Skip to content
Stock screener

NXL Nexalin Technology, Inc. stock chart & analysis

Conviction 49HealthcareScan · Thu, Nov 19, 2026

Nexalin Technology, Inc. (NXL) closed at $1.38 (-4.17%) on Nov 19, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 30, RS Rating 2, -95.9% from its 52-week high, -91.8% year to date. Sector: Healthcare · Electromedical & Electrotherapeutic Apparatus.

NXL$1.38-4.17%
ResistanceSupportVol 14
Loading chart…

Why NXL moved

From the StockSetups movers recaps that covered NXL, newest first. A recap states what was known that day.

  • Close+72.9%

    Nexalin Technology closed up 72.9% at $7.40, with volume hitting 64.6 million shares against a 20-day average of roughly 3.25 million — nearly 20× normal turnover. NXL also appeared in this morning's premarket movers scan; see our Premarket Movers Oct 1, 2026 recap for the early setup context.

    Top Stock Movers Oct 1, 2026: SSM, NXL, VEEA →
  • Premarket+48.6%

    The most prominent recent filing on NXL is a bearish 8-K filed September 28 flagging delisting risk from Nasdaq.

    Premarket Movers Oct 1, 2026: NXL, SDEV, VEEA →
Nexalin Technology, Inc.Electromedical & Electrotherapeutic Apparatuswww.nexalin.com ↗
Price1.38
Change-4.17%
Gap-4.17%
Rel volume0.50×
Avg volume24.1K
Avg $ vol38.16K
SMA 201.55
SMA 503.06
SMA 2009.73
Price vs 50-54.91%
Price vs 200-85.81%
MA stackbearish
50/200 cross—
Supertrenddown · 1.99
RSI (14)30
MACD hist0.13
MACD cross—
Stoch %K / %D22 / 39
ADX (14)19
+DI / −DI20 / 31
RSI divergence—
MACD divergence—
ATR %19.78%
ADR %9.54%
52w high33.60
52w low1.31
From 52w high-95.89%
Above 52w low+5.34%
New 52w highNo
SqueezeOn · 3d
Bollinger width28.24%
%B0.12
Donchian pos9.21%
Donchian high2.07
Donchian low1.31
AVWAP (52w high)8.43
vs AVWAP high-83.63%
AVWAP (52w low)1.48
vs AVWAP low-6.54%
OBV trendDown
Chaikin MF (20)-0.01
Today vs 20d0.50×
Avg vol (14d)18.11K
Avg vol (20d)24.1K
Avg $ vol (20d)38.16K
Market cap1.71M
RS Rating2 / 99
RS 3m (vs SPY)-79.63%
RS 6m (vs SPY)-84.85%
RS line new highNo
Trend template0/8
Technical rank4.9
1 week-7.38%
1 month-32.02%
3 months-86.15%
6 months-88.47%
1 year-95.66%
YTD-91.76%
P/E-0.21
P/B6.48
P/S5.66
P/FCF—
EPS-0.5000
Div yield—
ROE—
ROA-250.12%
Debt/Eq—
Current0.69
EV/EBITDA—
Gross margin79.65%
Net margin—
Rev growth78.78%
EPS growth-8.08%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value913.31K
Revenue78.3K
Net income-2.66M
Gross profit55.68K
Free cash flow—
IndustryElectromedical & Electrotherapeutic Apparatus
ExchangeNasdaq
Shares out20.58M
Employees8
ListedFri, Sep 16, 2022
Free float15.38M
Float %74.8%
Short interest—
Days to cover—
Short volume24.1%
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction49 / 100
Pattern quality—
Tech rank4.9 / 100
Group rank—
Status laneNo active setup
Setup direction—
Pattern family
Resistance6.76
Support1.33
Days since event—
Candle confirm—

Financials as of Wed, Sep 30, 2026 · quarterly.

NXL technical analysis

Trend

NXL is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 54.9% below the 50-day ($3.06) and 85.8% below the 200-day ($9.73). ADX(14) at 19 points to a weak trend — more range than direction. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 30, in oversold territory. The MACD histogram is positive. Its RS Rating of 2 puts its weighted 12-month performance ahead of about 2% of the US market.

Volume and volatility

Volume on the latest session ran 0.5× its 20-day average. It trades about $38,158 a day on average. ATR(14) is $0.2730, 19.8% of price — its typical daily range. Bollinger Bands are in a squeeze (3 sessions) — volatility is compressed. On-balance volume is trending down.

Key levels

The chart pattern's support is $1.33 and its resistance $6.76. The 52-week range is $1.31 to $33.60; price is 95.9% below the high and 5.3% above the low. The VWAP anchored at the 52-week high is $8.43, above price.

Performance

NXL returned -7.4% (1 week), -32.0% (1 month), -86.2% (3 months), -88.5% (6 months), -95.7% (1 year), -91.8% (year to date).

About Nexalin Technology, Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Electromedical & Electrotherapeutic Apparatus · Listed 2022 · 8 employees

SEC filings

EDGAR filings in NXL · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.